用斯佩索利马布和阿普雷米拉斯的联合治疗耐火性泛性性牛皮:一个病例报告
Yuwei Li1, Zhenyu Li2, Xinhong Hu1
1Department of Dermatology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Frontiers in medicine
|September 15, 2025
概括
综合性性牛皮 (GPP) 治疗可以通过结合抗素-36 (IL-36) 治疗与固酶4 (PDE4) 抑制剂进行长期缓解来改善病发,这为耐火病例提供了有希望的策略.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 泛性性牛皮 (GPP) 是一种严重的,危及生命的中性恋性皮肤病.
- GPP涉及复发性,全身炎症和潜在的器官衰竭.
- 传统疗法对于耐火性GPP通常是无效的.
研究的目的:
- 评估一个耐火性GPP患者的顺序治疗策略.
- 评估将斯佩索利马布 (抗IL-36) 与阿普雷米拉斯特 (PDE4抑制剂) 结合的疗效.
主要方法:
- 一个患有10年GPP病史的患者接受了单剂量斯佩索利马布,接着是阿普雷米拉斯.
- 对治疗的反应被监测到症状的消失和长期缓解.
主要成果:
- 斯佩索利马布控制了急性发作,随后的阿普雷米拉斯特在治疗后13个月内实现了持续的缓解.
- 患者经历了快速症状缓解,没有不良事件,生活质量得到改善.
结论:
- 一种连续的方法,将IL-36抑制用于急性GPP爆发与PDE4抑制用于维护,可能是一个可行的策略.
- 这种组合疗法在治疗耐火性GPP方面表现有前途,因此需要在更大规模的研究中进一步调查.
相关概念视频
Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499

